蛋白质稳定工作负载对多发性骨髓瘤中蛋白质酶抑制剂敏感性的影响
1Department of Genetics and Microbiology, Charles University and Research Center BIOCEV, Průmyslová 595, 252 50, Vestec, Czech Republic. jindrich.sedlacek@uochb.cas.cz.
Clinical and experimental medicine
|May 26, 2025
概括
多发性骨髓瘤细胞依赖于蛋白质稳定. 针对蛋白酶体抑制剂和其他途径的新组合疗法显示出克服耐药性和提高治疗疗效的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 多发性骨髓瘤 (MM) 的特点是基因组的改变和高免疫球蛋白的产生,导致对蛋白质稳定机制的依赖.
- 蛋白酶体抑制剂 (PI) 在MM治疗中至关重要,但由于自然和获得的耐药性而面临挑战,导致复发/耐药性疾病的预后不佳.
研究的目的:
- 审查最近关于MM细胞蛋白质稳定路径的发现.
- 探索针对PI的抗性,敏感性和逃脱机制.
- 为新型组合疗法提供理由,以提高PI的疗效.
主要方法:
- 对MM中调节蛋白质稳定性的分子机制的文献综述.
- 对PI的抗性和敏感性策略的分析.
- 识别新型药物点和组合策略.
主要成果:
- 毫米细胞严重依赖蛋白质折叠和降解途径.
- 对PI的耐药性是一个重要的临床挑战,导致疾病复发.
- 针对其他蛋白质稳定网络组件提供了克服抵抗的机会.
结论:
- 了解蛋白质静止的脆弱性是开发有效的MM疗法的关键.
- 将PI与向NRF1,氧化还原平衡,热冲击反应,UPR,自或VCP/p97的药物相结合,可以增加蛋白质毒性压力.
- 新的组合策略有望改善复发性/耐药性MM的结果.
相关概念视频
The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
The Proteasome
10.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.1K
Regulation of the Unfolded Protein Response
2.9K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.9K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K


